vandetanib + gemcitabine + capecitabine

**vandetanib + gemcitabine + capecitabine** is a combination regimen under investigation, primarily in advanced solid tumors like pancreatic and biliary tract cancers[1][2][4]. - **Vandetanib** is an oral small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGF), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosine kinases, aiming to inhibit tumor angiogenesis and proliferation[1][2][5]. - **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis, used as a cytotoxic antineoplastic drug administered intravenously[6][7]. - **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU) that interferes with DNA synthesis, also used for cytotoxic chemotherapy[6][7]. The combination aims to provide enhanced antitumor activity by disrupting complementary pathways involved in tumor growth and maintenance. The triplet regimen has been evaluated up to phase I—for safety, tolerability, and preliminary efficacy—with reported recommended phase II dosing in published research[1][2][4]. Results have shown promising activity but are not yet standard of care or approved; further clinical evaluation is warranted[1][2].

Other names

GemCap